Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
0.8532
+0.0166 (1.98%)
At close: Nov 18, 2026, 4:00 PM EST
0.8532
0.00 (0.00%)
After-hours: Nov 18, 2026, 4:00 PM EST
Marker Therapeutics Revenue
Marker Therapeutics had revenue of $1.29M in the quarter ending September 30, 2026, with 4.87% growth. This brings the company's total for the last twelve months to $3.83M, down -18.43% year-over-year. In the year 2025, Marker Therapeutics had annual revenue of $3.55M, down -46.19%. That makes Marker Therapeutics the 42,119th largest company in the world by revenue and 5,706th in the United States.
Revenue (ttm)
$3.83M
Revenue Growth
-18.43%
P/S Ratio
6.13
Revenue / Employee
$462,746
Employees
5
Market Cap
14.23M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.55M | -3.04M | -46.19% |
| Dec 31, 2024 | 6.59M | 3.28M | 99.06% |
| Dec 31, 2023 | 3.31M | -5.70M | -63.26% |
| Dec 31, 2022 | 9.01M | 7.77M | 625.90% |
| Dec 31, 2021 | 1.24M | 774.93K | 166.01% |
| Dec 31, 2020 | 466.79K | 253.59K | 118.95% |
| Dec 31, 2019 | 213.19K | 7.20K | 3.50% |
| Dec 31, 2018 | 205.99K | 22.93K | 12.53% |
| Dec 31, 2017 | 183.06K | -48.14K | -20.82% |
| Dec 31, 2016 | 231.20K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
MRKR News
- 2 days ago - Marker Therapeutics Quarterly report: Q3 2026 - Filings
- 4 weeks ago - Marker Therapeutics awarded $2.6M FDA Orphan Products development grant - TheFly
- 4 weeks ago - Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer - GlobeNewsWire
- 1 month ago - Marker Therapeutics highlights expanded manufacturing support of CDMO partner - TheFly
- 1 month ago - Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies - GlobeNewsWire
- 3 months ago - Marker Therapeutics Quarterly report: Q2 2026 - Filings
- 6 months ago - Marker Therapeutics Quarterly report: Q1 2026 - Filings
- 8 months ago - Marker Therapeutics Proxy statement: Proxy filing - Filings